RT Journal Article
SR Electronic
T1 Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.13.21255439
DO 10.1101/2021.04.13.21255439
A1 Diorio, Caroline
A1 Shraim, Rawan
A1 Vella, Laura A.
A1 Giles, Josephine R.
A1 Baxter, Amy E.
A1 Oldridge, Derek A.
A1 Canna, Scott W.
A1 Henrickson, Sarah E.
A1 McNerney, Kevin O.
A1 Balamuth, Frances
A1 Burudpakdee, Chakkapong
A1 Lee, Jessica
A1 Leng, Tomas
A1 Farrell, Alvin
A1 Lambert, Michele P.
A1 Sullivan, Kathleen E.
A1 John Wherry, E.
A1 Teachey, David T.
A1 Bassiri, Hamid
A1 Behrens, Edward M.
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.13.21255439.abstract
AB Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory symptoms. We performed a comprehensive analysis of the plasma proteome of more than 1400 proteins in children with SARS-CoV-2. We hypothesized that the proteome would reflect heterogeneity in hyperinflammation and vascular injury, and further identify pathogenic mediators of disease. Protein signatures demonstrated overlap between MIS-C, and the inflammatory syndromes macrophage activation syndrome (MAS) and thrombotic microangiopathy (TMA). We demonstrate that PLA2G2A is a key marker of MIS-C that associates with TMA. We found that IFNγ responses are dysregulated in MIS-C patients, and that IFNγ levels delineate clinical heterogeneity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCHOP Frontiers Program Immune Dysregulation Team National Institute of Allergy and Infectious Diseases National Cancer Institute Leukemia and Lymphoma Society COG ALSF Team Connor Childhood Cancer Foundation DOD ITMAT Jen and Fred FoxAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Children's Hospital of Philadelphia Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.